Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Abram, Michael E ^a   Ram, Renee R ^a   Margot, Nicolas A ^a   Barnes, Tiffany L ^a   White, Kirsten L ^a   Callebaut, Christian ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DOLUTEGRAVIR; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; MARAVIROC; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; CODON; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLONE DERIVATIVE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CODON USAGE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE D; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE F; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE G; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; CODON; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; MUTATION; PHENOTYPE; PHYSIOLOGY;

CODON; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; PHENOTYPE; QUINOLONES; RALTEGRAVIR POTASSIUM; TREATMENT OUTCOME;

EID: 85013151870     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172206     Document Type: Article

References (122)

1. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009; 50(5):529-36. doi: 10.1097/QAI.0b013e31819675e9 PMID: 19223785
2. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011; 365(7):637-46. doi: 10.1056/NEJMra1004180 PMID: 21848464
3. Johnson JA, Geretti AM. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother. 2010; 65(7):1322-6. doi: 10.1093/jac/dkq139 PMID: 20466851
4. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, Arias A. Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol. 2006; 299:51-82. PMID: 16568896
5. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006; 439(7074):344-8. doi: 10. 1038/nature04388 PMID: 16327776
6. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nature reviews Genetics. 2004; 5(1):52-61. doi: 10.1038/nrg1246 PMID: 14708016
7. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008; 197(6):867-70. doi: 10.1086/528802 PMID: 18269317
8. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010; 201(5):662-71. doi: 10.1086/650543 PMID: 20102271
9. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis. 2009; 48(2):239-47. doi: 10.1086/595703 PMID: 19086910
10. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008; 5(7):e158. doi: 10.1371/journal.pmed.0050158 PMID: 18666824
11. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, et al. Low-abundance drugresistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis. 2009; 199(5):693-701. doi: 10.1086/596736 PMID: 19210162
12. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5):363-71. doi: 10.1016/S1473-3099(11)70032-9 PMID: 21354861
13. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012; 14(1):17-27. PMID: 22297501
14. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother. 2011; 66(7):1467-80. doi: 10.1093/jac/dkr157 PMID: 21502281
15. Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther. 2011; 16(2):137-40. doi: 10.3851/IMP1750 PMID: 21447861
16. Department for Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC); http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 2016.
17. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016; 316(2):191-210. doi: 10.1001/jama.2016.8900 PMID: 27404187
18. Merck Sharp & Dohme Corp. ISENTRESS® (raltegravir) film-coated tablets, for oral use. ISENTRESS ® (raltegravir) chewable tablets, for oral use. ISENTRESS® (raltegravir) for oral suspension. U. S. Prescribing Information. New Jersey, USA. 2015.
19. Gilead Sciences Inc. VITEKTA® (elvitegravir) tablets, for oral use. U.S. Prescribing Information. Foster City, CA. 2014.
20. GlaxoSmithKline. TIVICAY (dolutegravir) tablets for oral use. U.S. Prescribing Information. Research Triangle Park, NC. 2015.
21. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment- naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007; 46(2):125-33. doi: 10.1097/QAI.0b013e318157131c PMID: 17721395
22. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010; 50(4):605-12. doi: 10.1086/650002 PMID: 20085491
23. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013; 63 (1):77-85. doi: 10.1097/QAI.0b013e31828ace69 PMID: 23412015
24. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010; 201(6):814-22. doi: 10.1086/650698 PMID: 20146631
25. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012; 12:27-35. doi: 10.1016/S1473-3099(11)70249-3 PMID: 22015077
26. Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, et al. A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results. Journal of Acquired Immune Deficiency Syndromes. 2016; 72(1):58-64. doi: 10.1097/QAI. 0000000000000940 PMID: 26829661
27. Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, Dejesus E, et al. A randomized, doubleblind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir- boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014; 65(3):e121-4. doi: 10.1097/QAI. 0000000000000089 PMID: 24346640
28. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013; 13 (11):927-35. doi: 10.1016/S1473-3099(13)70257-3 PMID: 24074642
29. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382 (9893):700-8. doi: 10.1016/S0140-6736(13)61221-0 PMID: 23830355
30. Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy- naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015; 70(5):515-9. doi: 10.1097/QAI.0000000000000790 PMID: 26262777
31. Park TE, Mohamed A, Kalabalik J, Sharma R. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther. 2015; 13(10):1195-212. doi: 10.1586/14787210.2015.1075393 PMID: 26293294
32. Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis. 2014; 58(3):423-31. doi: 10.1093/cid/cit697 PMID: 24145878
33. Gilead Sciences Inc. STRIBILD® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use. U.S. Prescribing Information. Foster City, CA. 2016.
34. Gilead Sciences Inc. GENVOYA® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use. US Prescribing Information. Foster City, CA. 2016.
35. ViiV Healthcare. TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral use. Research Triangle Park, NC. US Prescribing Information. 2014.
36. Boyd SD, Maldarelli F, Sereti I, Ouedraogo GL, Rehm CA, Boltz V, et al. Transmitted raltegravir resistance in an HIV-1 CRF-AG-infected patient. Antivir Ther. 2011; 16(2):257-61. doi: 10.3851/IMP1749 PMID: 21447876
37. Volpe JM, Ward DJ, Napolitano L, Phung P, Toma J, Solberg O, et al. Five antiretroviral drug classresistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection. Journal of the International Association of Providers of AIDS Care. 2015; 14(5):398-401. doi: 10.1177/2325957415596229 PMID: 26188010
38. Young B, Fransen S, Greenberg KS, Thomas A, Martens S, St Clair M, et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther. 2011; 16(2):253-6. doi: 10.3851/IMP1748 PMID: 21447875
39. Codoner FM, Pou C, Thielen A, Garcia F, Delgado R, Dalmau D, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res. 2010; 88(3):281-6. doi: 10.1016/j.antiviral.2010.09.016 PMID: 20883724
40. Gotte M. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Current opinion in virology. 2012; 2(5):644-50. doi: 10.1016/j.coviro.2012.08.004 PMID: 22964133
41. Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W. Substitutions at amino acid positions 143, 148, and 155 of HIV- 1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol. 2012; 86(13):7249-55. doi: 10.1128/JVI.06618-11 PMID: 22553340
42. Winters MA, Lloyd RM Jr., Shafer RW, Kozal MJ, Miller MD, Holodniy M. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS ONE. 2012; 7(7):e40514. doi: 10.1371/journal.pone.0040514 PMID: 22815755
43. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008; 52(4):1351-8. doi: 10.1128/AAC.01228-07 PMID: 18227187
44. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009; 83(22):11440-6. doi: 10.1128/JVI.01168-09 PMID: 19759152
45. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother. 2013; 57(6):2654-63. doi: 10.1128/AAC.02568-12 PMID: 23529738
46. Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, et al. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2009; 81(2):141-6. doi: 10.1016/j.antiviral.2008.10.007 PMID: 19027039
47. Huang W, Frantzell A, Fransen S, Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother. 2013; 57(9):4105-13. doi: 10.1128/AAC.00204-13 PMID: 23733474
48. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009; 37(4):1193-201. doi: 10.1093/nar/gkn1050 PMID: 19129221
49. Goodman DD, Hluhanich R, Waters JM, Margot NA, Fransen S, Gupta S, et al., editors. Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: A novel mutation L68V/I associates with E92Q and increases resistance [Poster 13]. XVII International HIV Drug Resistance Workshop; 2008 June 10-14; Stiges, Spain.
50. Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, et al. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother. 2010; 54(9):3938-48. doi: 10.1128/AAC.01720-09 PMID: 20479206
51. Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D'Arrigo R, et al. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1- infected patients, all naive to integrase inhibitors. J Antimicrob Chemother. 2010; 65(11):2305-18. doi: 10.1093/jac/dkq326 PMID: 20817922
52. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007; 12(4):563-70. PMID: 17668566
53. Myers RE, Pillay D. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol. 2008; 82(18):9228-35. doi: 10.1128/JVI.01535-07 PMID: 18596095
54. van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, Dwyer DE. HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology. 2009; 6:12. doi: 10.1186/1742-4690- 6-12 PMID: 19203393
55. Piralla A, Paolucci S, Gulminetti R, Comolli G, Baldanti F. HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients. Virology journal. 2011; 8:149. doi: 10.1186/1743- 422X-8-149 PMID: 21453487
56. Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother. 2010; 65(2):320-6. doi: 10.1093/jac/dkp423 PMID: 20007331
57. Reigadas S, Marcelin AG, Houssaini A, Yerly S, Descamps D, Plantier JC, et al. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes. J Antimicrob Chemother. 2013; 68(4):969-72. doi: 10.1093/jac/dks474 PMID: 23184711
58. Rhee SY, Sankaran K, Varghese V, Winters MA, Hurt CB, Eron JJ, et al. HIV-1 protease, reverse transcriptase, and integrase variation. J Virol. 2016; 90(13):6058-70. doi: 10.1128/JVI.00495-16 PMID: 27099321
59. Sichtig N, Sierra S, Kaiser R, Daumer M, Reuter S, Schulter E, et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother. 2009; 64(1):25-32. doi: 10.1093/jac/dkp153 PMID: 19447792
60. Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011; 83(5):751-9. doi: 10. 1002/jmv.22047 PMID: 21360548
61. Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother. 2015.
62. Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, et al. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients. J Antimicrob Chemother. 2011; 66(7):1481-3. doi: 10.1093/jac/dkr152 PMID: 21474479
63. Varghese V, Liu TF, Rhee SY, Libiran P, Trevino C, Fessel WJ, et al. HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses. 2010; 26(12):1323-6. doi: 10.1089/aid.2010.0123 PMID: 20961278
64. Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, et al. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009; 53(10):4275-82. doi: 10.1128/AAC.00397-09 PMID: 19651917
65. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS. 2008; 22:1875-84. doi: 10. 1097/QAD.0b013e328309efe3 PMID: 18753935
66. Cooper DA, Steigbigel RT, Gatell J, Rockstroh J, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistance HIV-1 infection. N Engl J Med. 2008; 359(4):355-65. doi: 10. 1056/NEJMoa0708978 PMID: 18650513
67. Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009; 63(4):795-804. Epub 2009/02/18. doi: 10.1093/jac/dkp014 PMID: 19221102
68. Han YS, Mesplede T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect Genet Evol. 2016; 46:286-291. doi: 10.1016/j.meegid.2016.06.047 PMID: 27353185
69. Theys K, Abecasis AB, Vandamme AM. HIV-1 drug resistance: where do polymorphisms fit in? Future microbiology. 2013; 8(3):303-6. doi: 10.2217/fmb.13.10 PMID: 23464368
70. Maiga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02-AG subtypes. Antivir Ther. 2009; 14(1):123-9. PMID: 19320246
71. Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, et al. Clinical efficacy of raltegravir against B and non- B subtype HIV-1 in phase III clinical studies. AIDS. 2011; 25(11):1365-9. doi: 10. 1097/QAD.0b013e328348065a PMID: 21522004
72. Llacer Delicado T, Torrecilla E, Holguin A. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals. J Antimicrob Chemother. 2016; 71(2):362-6. doi: 10.1093/jac/dkv333 PMID: 26546669
73. Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, et al. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother. 2010; 65(3):425-33. doi: 10.1093/jac/dkp477 PMID: 20056687
74. Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, et al. Evolution patterns of raltegravir- resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011; 17 (6):928-34. doi: 10.1111/j.1469-0691.2010.03375.x PMID: 20854427
75. Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009; 23(4):455-60. Epub 2009/01/24. doi: 10.1097/QAD.0b013e328323da60 PMID: 19165083
76. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010; 55(1):39-48. doi: 10. 1097/QAI.0b013e3181da1287 PMID: 20404738
77. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1 PMID: 19647866
78. Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, et al. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions. PLoS ONE. 2010; 5(4):e10311. Epub 2010/05/04. doi: 10.1371/journal.pone.0010311 PMID: 20436677
79. Waters JM, Margot N, Hluhanich R, Svarovskaia J, Harris J, Borroto-Esoda K, et al. Evoluti on of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns [Poster P116]. XVIII International HIV Drug Resistance Workshop; 2009 June 9-13; Fort Myers, Florida.
80. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment- experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013; 207(5):740-8. doi: 10.1093/infdis/jis750 PMID: 23225901
81. Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2015; 70(2):405-11. doi: 10.1093/jac/dku387 PMID: 25281399
82. Reigadas S, Masquelier B, Calmels C, Laguerre M, Lazaro E, Vandenhende M, et al. Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A. Antimicrob Agents Chemother. 2011; 55(7):3187-94. doi: 10.1128/AAC.00071-11 PMID: 21576445
83. Seki T, Suyama-Kagitani A, Kawauchi-Miki S, Miki S, Wakasa-Morimoto C, Akihisa E, et al. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother. 2015; 59(5):2596-606. doi: 10.1128/AAC.04844-14 PMID: 25691633
84. Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother. 2011; 55(8):3696-702. Epub 2011/06/02. doi: 10.1128/AAC.00566-11 PMID: 21628534
85. Cavalcanti JS, Lanca AM, Ferreira JL, Eira M, Dantas DS, Brigido LF. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen. Antiviral Res. 2012; 95:9-11. doi: 10. 1016/j.antiviral.2012.04.007 PMID: 22564967
86. Armenia D, Fabeni L, Alteri C, Di Pinto D, Di Carlo D, Bertoli A, et al. HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. J Antimicrob Chemother. 2015; 70(6):1865-73. doi: 10.1093/jac/dkv029 PMID: 25712318
87. Fransen S, Frantzell A, Gupta S, Petropoulos C, Huang W. Comparison of raltegravir susceptible and resistant viruses define the contribution of secondary mutations to reductions in raltegravir susceptibility [Poster 556]. Conference on Retroviruses and Opportunistic Infections (CROI); 2010 16-19 February; San Francisco, CA.
88. Haddad M, Huang W, Miller M, White K, Paquet A, Evans M, et al. Genotypic algorithm for predicting elvitegravir susceptibility: clinical validation and correlation with phenotype [Poster H-1574]. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2012 09-12 September; San Francisco, CA.
89. Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, et al. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral- naive patients. HIV Clin Trials. 2014; 15(5):218-30. doi: 10.1310/hct1505-218 PMID: 25350960
90. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment- naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008; 47(1):74-8. doi: 10. 1097/QAI.0b013e31815acab8 PMID: 17971715
91. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004; 292(2):191-201. doi: 10.1001/jama.292.2.191 PMID: 15249568
92. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med. 2003; 139(5, Part 1):313-21.
93. McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, Ledford R, et al., editors. Resistance and crossresistance to first generation integrase inhibitors: Insights from a phase 2 study of Elvitegravir (GS-9137) [Poster 9]. 16th International HIV Drug Resistance Workshop; 2007 June 12-16; Bridgetown, Barbados.
94. Gaur A, Abadi J, Wiznia A, Borkowsky W, Tudor-Williams G, Cunningham CK, et al., editors. Pharmacokinetics and safety of once-daily elvitegravir in HIV-infected adolescents [Poster 874]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010 February 16-19; San Francisco, CA.
95. Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. A randomized, double-blind comparison of single- tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus singletablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of Week 144 Results. J Acquir Immune Defic Syndr. 2014; 65(3):e118-21. doi: 10.1097/QAI. 0000000000000057 PMID: 24256630
96. White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, et al. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. Antivir Ther. 2015; 20(3):317-27. doi: 10.3851/IMP2885 PMID: 25321623
97. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, et al. Randomized, phase 2 evaluation of two single- tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011; 25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f PMID: 21412057
98. Post FA, Winston J, Andrade-Villanueva JF, Fisher M, Liu Y, Beraud C, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment. J Acquir Immune Defic Syndr. 2015; 68(3):310-3. doi: 10.1097/QAI.0000000000000476 PMID: 25469527
99. Kityo C, Squires K, Johnson M, Branco T, Post F, Kozyrev O, et al. The efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naïve women with HIV-1 infection: week 48 analysis of the phase 3, randomized, double-blind study [Poster 296]. European AIDS Clinical Society (EACS); 2015 21-24 October; Barcelona, Spain.
100. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2014; 67(1):52-8. doi: 10.1097/QAI.0000000000000225 PMID: 24872136
101. Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C. Rare emergence of drug resistance in HIV-1 treatment -naive patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin Trials. 2016; 17:78-87. doi: 10.1080/15284336.2016. 1142731 PMID: 26892863
102. Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Lawson E, Shao Y, et al. Safety, efficacy and pharmacokinetics of the integrase inhibitor-based E/C/F/TAF single-tablet regimen in treatment-naïve HIVinfected adolescents through 24 weeks of treatment [Poster 953]. Conference on Retroviruses and Opportunistic Infections; 2015 February 23-26; Seattle, WA.
103. Abram M, Margot NA, Cox S, Ram R, Porter DP, Kitrinos KM, et al. Pooled week 48 analysis of HIV-1 drug resistance in E/C/F/TAF phase 3 studies [Poster 496]. 23rd Annual Conference on Retroviruses and Opportunistic Infections (CROI); 2016 22-25 February; Boston, MA.
104. Fransen S, Gupta A, Huang W, Petropoulos C, Kiss L, Parkin N. Performance characteristics and validation of the phenosense HIV integrase assay [Poster H-1214]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2008 25-28 October; Washington, DC.
105. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006; 42(11):1608-18. doi: 10.1086/503914 PMID: 16652319
106. Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients-impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011; 90(3):164-7. doi: 10.1016/j.antiviral.2011.03.178 PMID: 21439330
107. Gutierrez C, Hernandez-Novoa B, Perez-Elias MJ, Moreno AM, Holguin A, Dronda F, et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials. 2013; 14(1):10-6. doi: 10.1410/hct1401-10 PMID: 23372110
108. Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther. 2015; 20(1):77-80. doi: 10.3851/IMP2780 PMID: 24831260
109. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother. 2011; 55(3):1114-9. doi: 10.1128/AAC.01492-10 PMID: 21173185
110. Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M, Group AAAW. Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations. AIDS Res Hum Retroviruses. 2012; 28(9):1157-60. doi: 10.1089/AID.2011.0326 PMID: 22236055
111. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE. 2009; 4(8):e6687. doi: 10.1371/journal.pone.0006687 PMID: 19690614
112. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011; 203(9):1204-14. doi: 10.1093/infdis/jir025 PMID: 21459813
113. Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, et al. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother. 2013; 57(3):1379-84. doi: 10.1128/AAC.01791-12 PMID: 23295935
114. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, et al. Study of genotypic and phenotypic HIV- 1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis. 2012; 205(4):557-67. doi: 10.1093/infdis/jir821 PMID: 22238474
115. Brun-Vezinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004; 9(4):465-78. PMID: 15456077
116. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther. 2002; 7(2):123-9. PMID: 12212924
117. Tang MW, Liu TF, Shafer RW. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012; 55(2):98-101. doi: 10.1159/000331998 PMID: 22286876
118. Hachiya A, Ode H, Matsuda M, Kito Y, Shigemi U, Matsuoka K, et al. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance. Antiviral Res. 2015; 119:84-88. doi: 10.1016/j. antiviral.2015.04.014 PMID: 25956162
119. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol. 2009; 49:377-94. doi: 10.1146/annurev.pharmtox. 011008.145553 PMID: 18928385
120. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011; 50(4):229-44. doi: 10. 2165/11584570-000000000-00000 PMID: 21348537
121. Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, et al. A cohort study of treatment- experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. Int J Antimicrob Agents. 2013; 42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016 PMID: 23562640
122. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, et al. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010; 24(14):2171-9. doi: 10.1097/QAD.0b013e32833cf265 PMID: 20647908